OmniAb
Provides antibody-discovery technologies that feed partner drug programs and royalty economics.
$4.40
After-hours close−0.07 (−1.47%)
At close$4.47(−3.04%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.12 | — | — |
| Aug 2026 | −$0.12 | −$0.05 | +58.3% |
| May 2026 | −$0.10 | −$0.06 | +40.0% |
| Mar 2026 | −$0.08 | −$0.11 | −37.5% |
| Nov 2025 | −$0.14 | −$0.14 | −2.9% |
The latest year is open to everyone — the 20 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Mar 2022 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | −$0.12 | — | — | $3.4M | — | — |
| Aug 6, 2026 | −$0.12 | −$0.05 | +58.3% | $4.7M | $13.4M | +185.9% |
| May 7, 2026 | −$0.10 | −$0.06 | +40.0% | $5.6M | $14.4M | +157.6% |
| Mar 4, 2026 | −$0.08 | −$0.11 | −37.5% | $9.0M | $8.4M | −7.0% |
| Nov 4, 2025 | −$0.14 | −$0.14 | −2.9% | $5.6M | $2.2M | −60.3% |
The latest year is open to everyone — the 20 quarters behind it read with an account. Sign in | ||||||
| Aug 6, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 18, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 20, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 30, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 12, 2022 | ||||||
| May 20, 2022 | ||||||
| Mar 28, 2022 | ||||||
| Mar 25, 2022 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||